CNO Financial Group, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CNO research report →
Range $48 – $70
Price Chart
About the company
Headquartered in Carmel, Indiana, and established in 1979, CNO Financial Group, Inc. operates across the United States, developing, marketing, and administering a broad spectrum of insurance and annuity products primarily for middle-income and senior individuals. The company's health insurance offerings span Medicare supplement plans, various supplemental health coverage (such as specified disease, accident, and hospital indemnity products), long-term care policies, and Medicare Advantage plans.
- CEO
- Gary C. Bhojwani
- IPO
- 2003
- Employees
- 3,200
- HQ
- Carmel, IN, US
Get TickerSpark's AI analysis on CNO
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $4.93B
- P/E
- 12.37
- Fwd P/E
- 9.82
- PEG
- 0.23
- P/S
- 1.11
- P/B
- 2.20
- EV/EBITDA
- 8.36
- Div Yield
- 1.26%
- Gross Margin
- 58.18%
- Op Margin
- 12.01%
- Net Margin
- 9.19%
- ROE
- 16.62%
- ROIC
- 2.17%
Latest fiscal year · YoY change
- Revenue
- $4.49B+0.9%
- Gross Profit
- $2.01B+18.1%
- Op Income
- $293.40M
- Net Income
- $229.30M-43.2%
- EPS
- $2.35-38.3%
- OCF Growth
- +7.6%
- FCF Growth
- +7.6%
- 52W High
- $59.15
- 52W Low
- $38.99
- 50D MA
- $55.08
- 200D MA
- $49.59
- Beta
- 0.81
- RSI (14)
- 39
- Avg Volume
- 951.57K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
CNO posted a strong third quarter with 47% EPS growth, broad-based sales momentum, and a raised full-year earnings outlook.· October 30, 2026
- Operating EPS was $1.90, up 47% year over year; excluding significant items, EPS was $1.42, up 48%.
- The company raised full-year 2026 operating EPS guidance to $5.05-$5.15 and now expects free cash flow of $220 million-$240 million.
- Sales momentum stayed strong: 17th straight quarter of sales growth, 15th straight quarter of agent count growth, and producing agents were up 4%.
- Insurance product margin improved 7%, net investment income increased 13%, and the new money rate stayed above 6% for the 15th consecutive quarter.
- Management highlighted ongoing Medicare Supplement strength, with Medicare Supplement NAP up 41% and total Medicare policies sold up 20%.
CNO reported third-quarter operating earnings per diluted share of $1.90, up 47% from the prior year. Excluding significant items associated with the annual actuarial review, operating EPS was $1.42, up 48% for the quarter and up 45% year-to-date. Total insurance product margin, excluding significant items, increased 7%, and net investment income rose 13% year over year. Book value per diluted share, excluding AOCI, was $41.29, up 8%. For 2026, management raised full-year operating EPS guidance to $5.05-$5.15 and expects free cash flow of $220 million-$240 million, with no change to target RBC, minimum holdco liquidity, or leverage ranges. They also lowered the full-year expense ratio outlook to 18.6%-18.8% from 18.8%-19.0% and the operating tax rate to about 20.5% from 21.5%.
Gary Bhojwani said CNO delivered an excellent quarter driven by its diversified business model, durable distribution, and repeatable execution. He emphasized the company’s middle-income focus, the strength of its captive agent model, and the fact that nearly all growth scorecard metrics improved. His tone was confident and upbeat, especially around Medicare Supplement, Worksite growth, and the company’s ability to finish the year strong.
Paul McDonough said the quarter reflected favorable insurance product margins, stronger net investment income, disciplined expenses, and capital management. He cited operating EPS of $1.90, a trailing 12-month expense ratio of 18.5% versus 19.0% a year ago, and $60 million of excess capital deployed to share repurchases, contributing to a 4% reduction in weighted average diluted shares outstanding. He also noted the annual actuarial review added $56.3 million to operating income, new money rate was 6.24%, and the company expects 2026 free cash flow of $220 million-$240 million while keeping capital and liquidity metrics within or above target.
Analysts pressed on the lower-end free cash flow outlook, and management said the change reflected timing and capital dynamics, including higher capital consumption from the FHLB program, lower expenses, and the third Bermuda reinsurance treaty, which closed October 1. They also asked whether CNO would cede more life business to Bermuda; management said the third treaty completed the transactions they had initially contemplated and that the decision was entirely theirs, not driven by regulators. Questions on Medicare and macro pressures were met with management’s view that demand remains resilient, especially because aging demographics and Medicare market disruption are supporting advice-driven sales and Medicare Supplement demand.
The bull case from this call is that CNO appears to be sustaining a long run of profitable growth, with sales growth across both divisions, record or near-record agent productivity, and improving returns. Management also sounded confident that Medicare Supplement demand, Worksite expansion, and Bermuda capital optimization can continue to support earnings and cash generation.
The main risks highlighted were that free cash flow is being influenced by capital deployment choices, including the FHLB program, tech modernization spend, and Bermuda treaty timing. Management also acknowledged some business-line volatility from D2C experimentation, higher morbidity in Medicare Supplement, and that current net investment income outperformance is unlikely to continue at the same level.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 97.3%
- Shares Outstanding
- 91.35M
- Float Shares
- 88.87M
of shares held by institutions
392 13F filers
Buy/sell ratio 0.25. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for CNO, newest first.
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock, Inc. | 13.40M | ▲ 15.88K |
| Vanguard Group Inc | 11.65M | ▼ 426.33K |
| Vanguard Portfolio Management LLC | 6.66M | ▼ 78.94K |
| State Street Corp | 4.16M | ▲ 6.43K |
| Vanguard Capital Management LLC | 4.05M | ▼ 36.34K |
| American Century Companies Inc | 3.65M | ▼ 106.18K |
| Franklin Templeton Inc | 3.43M | ▼ 447.10K |
| Dimensional Fund Advisors LP | 3.38M | ▼ 9.17K |
| Fuller & Thaler Asset Management, Inc. | 3.11M | ▼ 436.38K |
| Lsv Asset Management | 2.92M | ▼ 135.63K |
| Geode Capital Management, LLC | 2.85M | ▲ 222.30K |
| Aqr Capital Management LLC | 2.70M | ▲ 1.18M |
Held by 479 ETFs
Biggest fund positions in CNO by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 16, 26 | Zimpfer Matthew J. | sell | 18,651 |
| Nov 18, 26 | Zimpfer Matthew J. | other | 2,000 |
| Nov 17, 26 | Johnson Eric R. | other | 30,970 |
| Nov 17, 26 | Johnson Eric R. | sell | 20,170 |
| Nov 17, 26 | Johnson Eric R. | other | 30,970 |
| Sep 15, 26 | Williams Jeremy D. | other | 4,420 |
| Sep 16, 26 | Williams Jeremy D. | other | 3,240 |
| Sep 16, 26 | Williams Jeremy D. | sell | 3,240 |
| Sep 15, 26 | Williams Jeremy D. | sell | 4,420 |
| Sep 16, 26 | Williams Jeremy D. | sell | 1,122 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our CNO coverage
Recent articles, reports, and earnings notes.
Want a deeper read on CNO?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
CNO Financial Group Declares $0.18 Quarterly Dividend
prnewswire.com · Nov 13
Here's Why CNO Financial Can Be a Smart Addition to Your Portfolio
zacks.com · Nov 10
Four Course Records and 28 Olympic Trials Qualifiers Highlight Historic 2026 CNO Financial Indianapolis Monumental Marathon
gurufocus.com · Nov 7
Four Course Records and 28 Olympic Trials Qualifiers Highlight Historic 2026 CNO Financial Indianapolis Monumental Marathon
prnewswire.com · Nov 7
CNO Financial: 3 Key Takeaways for Long-Term Investors
fool.com · Nov 6
CNO Financial Group, Inc. (CNO) Hits Fresh High: Is There Still Room to Run?
zacks.com · Nov 6
Are You Looking for a Top Momentum Pick? Why CNO Financial (CNO) is a Great Choice
zacks.com · Nov 5
Here's Why CNO Financial (CNO) is a Strong Momentum Stock
zacks.com · Nov 5
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
